PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions
| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |

quinipristin-dalfopristin

  • quinipristin-dalfopristin has not been evaluated in the literature showing its role of altering the activities of CYP3A.
  • CYP3A
    Not evaluated in the literatureanastrozole
    atenolol
    atorvastatin
    caffeine
    cyproterone
    ethosuximide
    danazol
    delavirdine [a]
    digoxin
    gemfibrozil
    lapatinib
    metoprolol
    metronidazole
    mifepristone
    norfloxacin
    quinipristin-dalfopristin
    raloxifene
    repaglinide
    valproate

    Footnotes and References

    a.likely to be a major inhibitor based on subjective evaluation (≥ 2-fold AUC increase or ≥ 50% decrease in clearance of in vivo CYP probe).
    Disclaimer
    WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.